Compare Abeona Therapeutics Inc (ABEO) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Symbotic Inc — how do they compare? Abeona Therapeutics Inc trades at $7.42 (market cap $424.33M), while Symbotic Inc trades at $41.95 (market cap $5.21B). The key difference: Symbotic Inc is far larger — about 12.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | SYM | |
|---|---|---|
Market Cap | $424.33M | $5.21B |
Sector | Health | Technology |
52-Week High | $7.45 | $87.30 |
52-Week Low | $4.17 | $38.57 |
Enterprise Value | $279.23M | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
SYM trades at $40.18, down 1.46% with bearish technical signals despite analyst optimism. Recent Q3 2026 earnings missed estimates at $0.09 vs. $0.13 expected, though revenue grew 21.7% year-over-year. The company shows weak profitability with a 0.31% net margin but maintains strong cash flow generation of $517 million in 2025. Technical indicators show bearish momentum with support at $39 and resistance at $42.
Outlook remains mixed with 61% analyst buy ratings and $60 consensus target suggesting 49% upside, but execution risks persist after recent earnings misses. Key catalysts include margin expansion and system deployments, while risks include competitive pressure and volatile earnings performance. The stock offers growth potential but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
